Originalarbeiten ab 2010

 

Weide R
Versorgungsforschung in onkologischen Schwerpunktpraxen in Deutschland
Der Onkologe 2017; 23:1-6
Weide R, Rendenbach B, Grundheber M, Burkhard O, Behringer J, Maasberg M, Ehscheidt P, Strehl JW, Hansen R, Feiten S
Standard of care of patients with Chronic Myeloid Leukemia (CML) treated in community based oncology group practices between 2001-2015 in Rhineland-Palatinate (Germany)
Applied Cancer Research 2017;37:26
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma.
TumorDiagn u Ther 2016;37:393-397.
Feiten S, Dünnebacke J, Friesenhahn V, Heymanns J, Köppler H, Meister R, Thomalla J, van Roye C, Wey D, Weide R
Follow-up Reality for Breast Cancer Patients – Standardised Survey of Patients and Physicians and Analysis of Treatment Data
Geburtshilfe Frauenheilkd 2016; 76(05): 557-563
Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, van Roye C, Thomalla J
Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice
SpringerPlus (2016) 5:270
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014
Oncol Res Treat 2016;39:41-44.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma.
Dtsch Med Wochenschr 2015;140(19):e201-6.
Kurbacher CM, Fietz T, Diel I, Egert M, Hurtz H-J, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens C, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein RW.
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim – First Interim Analysis.
Oncol Res Treat 2015; 38: 221–229.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.
SpringerPlus 2014 3:535.
Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R
Breast cancer morbidity – questionnaire survey of patients on the long term effects of disease and adjuvant therapy.
Dtsch Arztebl Int 2014; 111: 537-44.
Herth I, Dietrich S, Benner A, Hegenbart U, Rieger M, Stadtherr P, Bondong A, Tran TH, Weide R, Hensel M, Knauf W, Franz-Werner J, Welslau M, Procaccianti M, Görner M, Meissner J, Luft T, Schönland S, Witzens-Harig M, Zenz T, Ho AD, Dreger P
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison.
Ann Oncol. 2014;25(1):200-6.
Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, Mergenthaler U, Thomalla J, van Roye C, Weide R
Psychosocial Distress in Caregivers of Patients with a Metastatic Solid Tumor in Routine Care: A Survey in a Community Based Oncology Group Practice in Germany.
Cancer and Clinical Oncology 2013,2(2):1-10.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, Mergenthaler U, van Roye C, Köppler H
Improved Survival of HER2-Positive Metastatic Breast Cancer in Routine Care
Cancer and Clinical Oncology 2013,2(1):17-27
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H
Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Leuk Lymphoma. 2013;54(8):1640-6.
Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M; GCLLSG
Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
Br J Haematol. 2012;158(2):238-41.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Mergenthaler U, Thomalla J, van Roye C, Köppler H
Identifying Caregivers and Their Meaning for Patients with Metastatic Solid Tumours in Routine Care: A Survey at a Community-Based Oncology Group Practice in Germany
Cancer and Clinical Oncology 2012;1(1):41-51
Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer K-A, Schlenk R, Ganser A, Hofmann W-K, Aul C, Krieger O, Kündgen A, Haas R, Hasford J and Giagounidis A
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
Leukemia 2012;26(6):1286-92.
Mergenthaler U, Heymanns J, Köppler H, Thomalla J, van Roye C, Schenk J, Weide R
Evaluation of psychosocial distress in patients treated in a community-based oncology group practice in Germany
Ann Oncol. 2011;22(4):931-8.
Weide R, Koeppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review
J Cancer Res Ther. 2010;6(1):31-5.
Köppler H, Heymanns J, Thomalla J, Kleboth K, Weide R
The impact of new treatment options for advanced colorectal cancer on routine care: Results of a retrospective analysis of 206 consecutive patients treated in a community based oncology group practice
Eur J Cancer Care (Engl.) 2010;19(6):795-802.